CN Patent

CN105367552A — 来那替尼马来酸盐的新晶型及其制备方法

Assigned to Crystal Pharmatech Co Ltd · Expires 2016-03-02 · 10y expired

What this patent protects

本发明涉及(2E)-N-{4-[3-氯-4-(2-吡啶基甲氧基)苯胺基]-3-氰基-7-乙氧基-6-喹啉基}-4-(二甲基氨基)-2-丁烯酰胺马来酸盐的新晶型及其制备方法。本发明的式(I)化合物的马来酸盐的新晶型，具有溶解度高、良好的稳定性、工艺可开发和易处理性等有利性能，且制备方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

本发明涉及(2E)-N-{4-[3-氯-4-(2-吡啶基甲氧基)苯胺基]-3-氰基-7-乙氧基-6-喹啉基}-4-(二甲基氨基)-2-丁烯酰胺马来酸盐的新晶型及其制备方法。本发明的式(I)化合物的马来酸盐的新晶型，具有溶解度高、良好的稳定性、工艺可开发和易处理性等有利性能，且制备方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN105367552A
Jurisdiction
CN
Classification
—
Expires
2016-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmatech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.